WO1999038455A1 - Stent-greffon intraluminal encapsule et procede de fabrication associe - Google Patents

Stent-greffon intraluminal encapsule et procede de fabrication associe Download PDF

Info

Publication number
WO1999038455A1
WO1999038455A1 PCT/US1998/008994 US9808994W WO9938455A1 WO 1999038455 A1 WO1999038455 A1 WO 1999038455A1 US 9808994 W US9808994 W US 9808994W WO 9938455 A1 WO9938455 A1 WO 9938455A1
Authority
WO
WIPO (PCT)
Prior art keywords
stent
endoluminal
expanded polytetrafluoroethylene
endoluminal stent
polytetrafluoroethylene
Prior art date
Application number
PCT/US1998/008994
Other languages
English (en)
Inventor
Brendan J. Mccrea
Tarun J. Edwin
Christopher E. Banas
Original Assignee
Impra, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US1998/002361 external-priority patent/WO1998033453A2/fr
Application filed by Impra, Inc. filed Critical Impra, Inc.
Priority to EP98918939A priority Critical patent/EP1054646A1/fr
Priority to JP2000529191A priority patent/JP4057238B2/ja
Priority to AU71759/98A priority patent/AU733860B2/en
Priority to CA002318829A priority patent/CA2318829C/fr
Publication of WO1999038455A1 publication Critical patent/WO1999038455A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/04—Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
    • A61F2/06—Blood vessels
    • A61F2/07—Stent-grafts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/95—Instruments specially adapted for placement or removal of stents or stent-grafts
    • A61F2/962—Instruments specially adapted for placement or removal of stents or stent-grafts having an outer sleeve
    • A61F2/966—Instruments specially adapted for placement or removal of stents or stent-grafts having an outer sleeve with relative longitudinal movement between outer sleeve and prosthesis, e.g. using a push rod
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/95—Instruments specially adapted for placement or removal of stents or stent-grafts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/08—Materials for coatings
    • A61L31/10—Macromolecular materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/86—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
    • A61F2/90—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/04—Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
    • A61F2/06—Blood vessels
    • A61F2/07—Stent-grafts
    • A61F2002/072—Encapsulated stents, e.g. wire or whole stent embedded in lining
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2400/00—Materials characterised by their function or physical properties
    • A61L2400/16—Materials with shape-memory or superelastic properties

Definitions

  • the present invention relates generally to implantable intraluminal devices, particularly intraluminal stents. Because of the open lattice found in most intraluminal stents, a primary problem with these types of device is occlusion of the vessel occurring after stent placement.
  • Tissue ingrowth and neointimal hyperplasia significantly reduces the open diameter of the treated lumen over time, requiring additional therapies.
  • the present invention incorporates the use of a biocompatible barrier material that prevents or delays the tissue ingrowth and neointimal hyperplasia, thus maintaining luminal patency for longer periods after initial treatment.
  • ePTFE expanded polytetrafluoroethylene
  • the present invention utilizes a radially expandable ePTFE material, such as that described in co-pending International patent application Serial No.
  • the inventive intraluminal stent-graft device may be implanted either by percutaneous delivery using an appropriate delivery system, a cut-down procedure in which a surgical incision is made and the intraluminal device implanted through the surgical incision, or by laparoscopic or endoscopic or endoscopic delivery. More particularly the present invention relates to shape memory alloy and self-expanding endoluminal stents which are at least partially encapsulated in a substantially monolithic expanded polytetrafluoroethylene (“ePTFE”) covering.
  • ePTFE expanded polytetrafluoroethylene
  • an endoluminal stent which has a reduced diametric dimension for endoluminal delivery and a larger in vivo final diametric diameter, is encapsulated in an ePTFE covering which circumferentially covers both the luminal and abluminal walls along at least a portion of the longitudinal extent of the endoluminal stent.
  • the endoluminal stent is preferably fabricated from a shape memory alloy which exhibits either shape memory or pseudoelastic properties or from an elastic material having an inherent spring tension.
  • the endoluminal stent is encapsulated in the ePTFE covering in the stent' s reduced diametric dimension and is balloon expanded in vivo to radially deform the ePTFE covering.
  • the endoluminal stent may be either one which exhibits thermal strain recovery, pseudoelastic stress-strain behavior or elastic behavior at mammalian body temperature. While in its reduced diametric dimension, the ePTFE encapsulating covering integrally constrains the endoluminal stent from exhibiting either thermal strain recovery, pseudoelastic stress-strain behavior or elastic behavior at mammalian body temperature.
  • an endoluminal stent fabricated of a shape memory alloy is encapsulated in its final diametric dimension and the encapsulated intraluminal stent-graft is manipulated into its reduced diametric dimension and radially expanded in vivo under the influence of a martensite to austenite transformation.
  • a self-expanding intraluminal stent fabricated of a material having an inherent spring tension, is encapsulated in its final diametric dimension and manipulated to a reduced diametric dimension and externally constrained for intraluminal delivery.
  • the spring tension exerted by the self-expanding stent radially expands both the stent and the ePTFE encapsulating covering to a radially enlarged diameter.
  • the endoluminal stent is fabricated from a material having an inherent elastic spring tension and it is encapsulated at a reduced dimension suitable for endoluminal delivery and balloon expanded in vivo to radially deform the ePTFE covering.
  • Shape memory alloys are a group of metallic materials that demonstrate the ability to return to a defined shape or size when subjected to certain thermal or stress conditions. Shape memory alloys are generally capable of being plastically deformed at a relatively low temperature and, upon exposure to a relatively higher temperature, return to the defined shape or size prior to the deformation. Shape memory alloys may be further defined as one that yields a thermoelastic martensite. A shape memory alloy which yields a thermoelastic martensite undergoes a martensitic transformation of a type that permits the alloy to be deformed by a twinning mechanism below the martensitic transformation temperature. The deformation is then reversed when the twinned structure reverts upon heating to the parent austenite phase.
  • the austenite phase occurs when the material is at a low strain state and occurs at a given temperature.
  • the martensite phase may be either temperature induced martensite (TIM) or stress-induced martensite (SIM).
  • TIM temperature induced martensite
  • SIM stress-induced martensite
  • M shape memory material
  • M d the material first deforms elastically and when a critical stress is reached, it begins to transform by the formation of stress-induced martensite.
  • a s the behavior when the deforming stress is released differs.
  • Shape memory characteristics may be imparted to a shape memory alloy by heating the metal at a temperature above which the transformation from the martensite phase to the austenite phase is complete, i.e., a temperature above which the austenite phase is stable.
  • the shape of the metal during this heat treatment is the shape "remembered.”
  • the heat treated metal is cooled to a temperature at which the martensite phase is stable, causing the austenite phase to transform to the martensite phase.
  • the metal in the martensite phase is then plastically deformed, e.g., to facilitate its delivery into a patient's body.
  • a temperature above the martensite to austenite transformation temperature e.g., body temperature
  • shape memory is used in the art to describe the property of a material to recover a pre-programmed shape after deformation of a shape memory alloy in its martensitic phase and exposing the alloy to a temperature excursion through its austenite transformation temperature, at which temperature the alloy begins to revert to the austenite phase and recover
  • the term "pseudoelasticity" is used to describe a property of shape memory alloys where the alloy is stressed at a temperature above the transformation temperature of the alloy and stress-induced martensite is formed above the normal martensite formation temperature. Because it has been formed above its normal temperature, stress-induced martensite reverts immediately to undeformed austenite as soon as the stress is removed provided the temperature remains above the transformation temperature.
  • the martensitic transformation that occurs in the shape memory alloys yields a thermoelastic martensite and develops from a high-temperature austenite phase with long-range order.
  • the martensite typically occurs as alternately sheared platelets, which are seen as a herringbone structure when viewed metallographically.
  • the transformation although a first-order phase change, does not occur at a single temperature but over a range of temperatures that varies with each alloy system. Most of the transformation occurs over a relatively narrow temperature range, although the beginning and end of the transformation during heating or cooling actually extends over a much larger temperature range.
  • the transformation also exhibits hysteresis in that the transformations on heating and on cooling do not overlap. This transformation hysteresis varies with the alloy system.
  • thermoelastic martensite phase is characterized by having a low energy state and glissile interfaces, which can be driven by small temperature or stress changes.
  • a thermoelastic martensite phase is crystallographically reversible.
  • the herringbone structure of athermal martensite essentially consists of twin-related, self-accommodating variants. The shape change among the variants tends to cause them to eliminate each other. As a result, little macroscopic strain is generated.
  • stress-induced martensite or when stressing a self-accommodating structure, the variant that can transform and yield the greatest shape change in the direction of the applied stress is stabilized and becomes dominant in the configuration. This process creates a macroscopic strain, which is recoverable as the crystal structure reverts to austenite during reverse transformation.
  • shape memory alloys vary greatly over the transformation temperature range. Martensite phase alloys may be deformed to several percent strain at quite a low stress, whereas the austenite phase alloy has much higher yield and flow stresses.
  • the a martensite phase shape memory allow will remember its unstrained shape and revert to its austenite phase.
  • the martensite phase can be stress-induced. Once stress-induced martensite occurs, the alloy immediately strains and exhibits the increasing strain at constant stress behavior. Upon unloading of the strain, however, the shape memory alloy reverts to austenite at a lower stress and shape recovery occurs, not upon the application of heat but upon a reduction of stress. This effect, which causes the material to be extremely elastic, is known as pseudoelasticity and the effect is nonlinear.
  • the present invention preferably utilizes an binary, equiatomic nickel-titanium alloy because of its biocompatibility and that such an alloy exhibits a transformation temperature within the range of physiologically-compatible temperatures.
  • Nickel-titanium alloys exhibit moderate solubility for excess nickel or titanium, as well as most other metallic elements, and also exhibits a ductility comparable to most ordinary alloys. This solubility allows alloying with many of the elements to modify both the mechanical properties and the transformation properties of the system. Excess nickel, in amounts up to about 1%, is the most common alloying addition.
  • a f Temperature The temperature at which a shape memory alloy finishes transforming to Austenite upon heating.
  • A_. Temperature The temperature at which a shape memory alloy starts transforming to Austenite upon heating.
  • Austenite The stronger, higher temperature phase present in NiTi.
  • Hysteresis The temperature difference between a phase transformation upon heating and cooling. In NiTi alloys, it is generally measured as the difference between A ⁇ and M ⁇ ,.
  • My Temperature The temperature at which a shape memory alloy finishes transforming to Martensite upon cooling.
  • M s Temperature The temperature at which a shape memory alloy starts transforming to Martensite upon cooling. Martensite: The more deformable, lower temperature phase present in NiTi.
  • Phase Transformation The change from one alloy phase to another with a change in temperature, pressure, stress, chemistry, and/or time.
  • Shape Memory The ability of certain alloys to return to a predetermined shape upon heating via a phase transformation.
  • Pseudoelasticity The reversible non-linear elastic deformation obtained when austenitic shape memory alloys are strained at a temperature above the ARIC but below M d , the maximum temperature at which pseudoelasticity is obtained.
  • Thermoelastic Martensitic Transformation A diffusionless, thermally reversible phase transformation characterized by a crystal lattice distortion.
  • a self-expanding intraluminal stent such as a GIANTURCO stent or a pseudoelastic shape memory stent
  • Figure 1 is a perspective view of the ePTFE encapsulated intraluminal stent in accordance with the present invention.
  • Figure 2A is a perspective view of an ePTFE encapsulated intraluminal stent encapsulated at its reduced diametric dimension for intraluminal delivery and balloon assisted expansion in vivo.
  • Figure 2B is a perspective view of the ePTFE encapsulated intraluminal stent of Figure 2A illustrating the ePTFE encapsulated intraluminal stent after balloon assisted expansion.
  • Figure 3 is a side elevational, longitudinal cross-sectional view of the inventive ePTFE encapsulated intraluminal stent encapsulated at its nominal in vivo dimension.
  • Figure 4 is a side elevational, longitudinal cross-sectional view of the inventive ePTFE encapsulated stent of Figure 4, illustrating the ePTFE encapsulated intraluminal stent partially at a reduced intraluminal delivery diameter deformed to a relatively reduced diameter suitable for intraluminal delivery, mounted on a delivery catheter having an axially moveable constraining sheath which constrains the ePTFE encapsulated self-expanding intraluminal stent in its relatively reduced diametric dimension.
  • Figure 5 is a scanning electron micrograph, taken at 300X magnification, of an outer surface of the radially expanded ePTFE material used to encapsulate the balloon assisted radially expandable encapsulated NITINOL stent of the present invention.
  • Figure 6 is a scanning electron micrograph, taken at 300X magnification, of an inner surface of the ePTFE material used to encapsulate the balloon assisted radially expandable encapsulate NITINOL stent of the present invention.
  • Figure 7 is a scanning electron micrograph, taken at 300X magnification, of an outer surface of the ePTFE material used to encapsulate a self-expanding NITINOL or spring tension stent in accordance with the present invention.
  • FIG. 8 is a scanning electron micrograph, taken at 300X magnification, of an inner surface of the ePTFE material used to encapsulate a self-expanding NITINOL or spring tension stent of the present invention.
  • Figure 9A is a flow diagram illustrating the inventive process steps to thermomechanically deform a pre-programmed shape memory stent to a reduced diametric dimension for encapsulation or endoluminal delivery.
  • Figure 9B is a flow diagram illustrating the inventive process steps to encapsulate a shape memory alloy stent and a self-expanding stent to make each preferred embodiment of the present invention.
  • Figure 1 illustrates the ePTFE encapsulated intraluminal stent 10 of the present invention in a radially enlarged diametric dimension.
  • the inventive ePTFE encapsulated intraluminal stent 10 of the present invention is best illustrated with reference to several preferred embodiments thereof.
  • the first preferred embodiment is depicted in Figures 2A-2B and consists generally of an intraluminal stent 12 made of a shape memory alloy which is at least partially encapsulated in a substantially monolithic ePTFE covering 14 while in a relatively smaller diametric dimension O ⁇ and is radially expandable in vivo under the influence of a radially outwardly directed force which radially deforms the ePTFE covering 14 and releases the stress exerted on the intraluminal stent 12 while at body temperature to permit the intraluminal stent to undergo deformation to a larger diametric dimension D 2 .
  • Figures 3-4 generically depict the second, third and fourth preferred embodiments of the present invention an intraluminal stent 20 which is at least partially encapsulated within a substantially monolithic ePTFE covering 14 over at least an entire circumferential portion of the luminal and abluminal surfaces of the intraluminal stent 12.
  • the second, third and fourth preferred embodiments differ from one another based upon the type of intraluminal stent 20 utilized and whether the encapsulated stent device is intended to radially expand in vivo under the influence of the shape memory behavior or elastic spring tension behavior of the intraluminal stent 20 or whether in vivo delivery will be balloon catheter assisted.
  • the second preferred embodiment of the present invention consists generally of an intraluminal stent 20 made of a shape memory alloy which is at least partially encapsulated in a
  • the third preferred embodiment of the present invention consists generally of a self- expanding intraluminal stent 20 made from either an elastic spring material or of a pseudoelastic shape memory material, and is at least partially encapsulated in a substantially monolithic ePTFE covering 14 while in a relatively small diametric dimension D 2 such that the ePTFE encapsulating covering 14 acts to impart strain upon the intraluminal stent 20 and constrain the intraluminal stent from radial expansion to a relatively larger diametric dimension O 1 , until intraluminally delivered and the ePTFE encapsulation radially deformed at body temperature to release the strain exerted by the ePTFE covering 14, thereby permitting the self-expanding intraluminal stent 20 to radially deform to a relatively larger diametric dimension.
  • the fourth preferred embodiment of the present invention consists generally of a self- expanding intraluminal stent 20 made from either an elastic spring material or a pseudoelastic shape memory material, which is at least partially encapsulated in a substantially monolithic ePTFE covering 14 while in a relatively larger diametric dimension D 2 such that the ePTFE encapsulating covering 14 restrains the intraluminal stent from further self-expansion.
  • the assembly is then worked, such as by crimping, calendaring, folding, compressing or the like to reduce its diametric dimension to the reduced diametric dimension D j suitable for endoluminal delivery and constrained by an external constraining sheath 22.
  • the constraining sheath 22 is removed to release the constraining force and the intraluminal stent is permitted to elastically expand as denoted by arrows 24, carrying the ePTFE covering 14 into contact with the intraluminal tissue (not shown).
  • intraluminal stent type and whether the intraluminal encapsulated stent is intended for intraluminal delivery by balloon deformation of the ePTFE covering or whether delivery will occur due to the self-expanding property of the intraluminal encapsulated stent and non- deformation of the ePTFE covering.
  • a balloon expandable encapsulated shape memory alloy intraluminal stent 10 consists generally of an endoluminal stent 12 fabricated of a shape memory alloy, preferably one having an A s value at a physiologically acceptable temperature compatible with tissue conservation, such as equiatomic nickel-titanium alloys known as NITINOL.
  • the endoluminal stent 12 is at least partially encapsulated in a substantially monolithic ePTFE covering 14 while the endoluminal stent 12 is in a relatively smaller diametric dimension O .
  • the substantially monolithic ePTFE covering 14 is a continuous integral tubular structure, is free of seams and covers at least part of both the luminal and abluminal surfaces about an entire circumferential section of the endoluminal stent 12 along at least a portion of the longitudinal axis of the intraluminal stent 12.
  • the substantially monolithic ePTFE covering 14 is characterized by having a node and fibril microstructure where the nodes are oriented generally perpendicular to the longitudinal axis 30 of the stent 12 and the fibrils are oriented generally parallel to the longitudinal axis 30 of the stent 12, with the distance between adjacent nodes being termed the "internodal distance.”
  • the substantially monolithic ePTFE covering 14 is preferably radially deformable at applied pressures less than about six atmospheres, most preferably less than about three atmospheres, due to the deformable nature of the nodes along their longitudinal axis, i.e., radial relative to the substantially monolithic ePTFE covering 14 and perpendicular to the longitudinal axis 30 of the intraluminal stent 12.
  • the encapsulated intraluminal stent 10 is radially expandable in vivo under the influence of a radially outwardly directed force, such as from a balloon catheter, which radially deforms the ePTFE covering to a second relative large diametric dimension, D 2 , to release the constraining stress exerted on the intraluminal stent by the ePTFE covering while the radially outwardly directed force, such as from a balloon catheter, which radially deforms the ePTFE covering to a second relative large diametric dimension, D 2 , to release the constraining stress exerted on the intraluminal stent by the ePTFE covering while the
  • intraluminal stent 12 is at body temperature.
  • the simultaneous release of the constraining force exerted by the ePTFE covering permits the intraluminal stent 12 to undergo thermomechanical deformation to a larger diametric dimension.
  • a balloon assisted encapsulated shape memory alloy stent was constructed by longitudinally slitting about 5 cm of a 60 cm length of a first seamless unsintered expanded PTFE tube having an inner diameter of 3.0 mm. The slit ends were gripped into a fixture allowing the tube to hang vertically. At the opposite end of the tube, a length of wire was attached to assist in threading the tubing through the inner diameter of the stent. The thickness of the ePTFE layer was measured to be about 0.35 mm using a snap gauge.
  • the ePTFE tube has a node-fibril microstructure in which the fibrils are oriented parallel to the longitudinal axis of the tube throughout the wall thickness of the ePTFE tube.
  • a 10 X 40 mm shape memory endoluminal stent was placed in a cold, dry environment at approximately -40° C and compressed about a mandrel having an outer diameter of 4.5 mm by mechanically deforming the stent to circumferentially conform to the outer diameter of the mandrel.
  • the compressed stent was then removed from the cold, dry environment and concentrically passed over the outer diameter of the vertically hanging ePTFE tube, passing the wire through the stent lumen to assist in engaging the stent about the abluminal surface of the ePTFE tube without tearing or marring the ePTFE tube.
  • a 3.3 mm diameter mandrel was then slid into the lumen of the ePTFE tube/stent assembly, and the tubing secured to the mandrel using ⁇ _ inch strips of tetrafluoroethylene (TFE) tape.
  • TFE tetrafluoroethylene
  • the assembly was then removed from the vertical hanging fixture.
  • the mandrel bearing the first ePTFE tube and the shape memory stent was then passed into the lumen of the second tube, until the stent was approximately centered on the mandrel.
  • the wall thickness of the second layer was measured as described above, and the thickness was found to be about 0.35
  • the fibrils were oriented parallel to the longitudinal axis of the tube.
  • the ends of the second tube were also wrapped with strips of TFE tape to secure to the mandrel.
  • the assembly was then placed in a helical winding wrapping machine which tension wraps the assembly with a single overlapping layer of V2 inch TFE tape.
  • the overlap of the winding was about 70%.
  • the tension exerted by the TFE wrapping tape compresses the ePTFE/stent/ePTFE composite structure against the mandrel, thereby causing the layers of ePTFE to come into intimate contact through the interstices of the shape memory stent.
  • the tension wrap was set to exert 1.7 psi pressure circumferentially around the ePTFE/stent/ePTFE and mandrel assembly.
  • the wrapped assembly was placed into a radiant heat furnace, which had been preheated to a 337° C set point. The assembly remained in the furnace for about 7 minutes, and was removed. The heated assembly was allowed to cool for a period of time sufficient to permit manual handling of the assembly. After cooling the TFE helical wrap was unwound from the sample and discarded. The now ePTFE encapsulated stent assembly was then concentrically rotated about the axis of the mandrel to release any adhesion between the inner ePTFE layer and the mandrel. The ePTFE encapsulated stent assembly, still on the mandrel, was placed into a laser trimming fixture to trim excess ePTFE materials away from the proximal and distal ends.
  • the trimmed encapsulated stent was removed from the mandrel.
  • Five encapsulated stent samples were prepared in accordance with the foregoing description and were each placed a balloon on a 10 mm by 4 cm PTA balloon dilation catheter. The device was then placed into a temperature controlled water bath maintained at 37° C. The balloon was pressurized using a saline filled inflator, thereby expanding the encapsulated stent.
  • Each encapsulated stent device was radially expanded under the influence of balloon deformation of the ePTFE encapsulating covering with full radial deformation to a 10 mm inner diameter occurring at inflation pressures between 2 and 4 atmospheres.
  • the radially expanded encapsulated stents obtained from Example 1 were placed over a 10 mm diameter stainless steel mandrel, and spiral wrapped using 2 inch ePTFE tape as described above.
  • the wrapped assembly was placed again into a radiant heat furnace, which had been preheated to 337° C set point. The assembly remained in the furnace for about 10 minutes, and was removed. The heated assembly was allowed to cool for a period of time sufficient to permit manual handling of the assembly. After air cooling, the ends of the mandrel was engaged in two rings and the TFE helical wrap was unwound from the encapsulated stent samples and discarded.
  • the encapsulated stents were concentrically rotated about the axis of the mandrel to release adhesion between the luminal ePTFE surface of the encapsulated stent and the mandrel.
  • the encapsulated stent was next cooled to about -20 °C in a cold dry environment and allowed to equilibrate for 30 minutes.
  • the cooled encapsulated stent was then rolled between 2 plates to successively reduce the encapsulated stent inner diameter to about 3.5 mm, representing a reduction of about 40% from the radially expanded inner diameter of the encapsulated stent.
  • the encapsulated stent at the reduced inner diameter of 3.5 mm was fully inserted into a constraining sheath having an inner diameter of approximately 3.7 mm.
  • the externally constrained encapsulated stent was then removed from the cold environment, and placed into a water bath maintained at a temperature of 37° C.
  • a pusher rod was inserted into the constraining sheath and impinged upon one end of the constrained encapsulated stent.
  • the encapsulated stent was ejected from constraining sheath.
  • the stent was ejected, it radially dilated from its compressed state, and re-assumed the original fully expanded diametric dimension of about 10 mm inner diameter.
  • the second preferred embodiment of the present invention consists generally of an intraluminal stent 20 made of a shape memory alloy which is at least partially encapsulated in a substantially monolithic ePTFE covering 14 while in a relatively larger diametric dimension D 2 and in the austenite phase, which is thermomechanically deformed to a
  • a thermally deployed encapsulated shape memory alloy stent was constructed by placing a 40 cm length of a first seamless expanded PTFE tube over a 10 mm cylindrical stainless steel mandrel.
  • the inner diameter of the ePTFE tube was of a sufficient size to permit an interference fit with the mandrel.
  • the thickness of the ePTFE layer was measured to be about 0.20 mm by taking a radial slice of the seamless tube, and evaluated by light microscopy incorporating a calibrated reticle.
  • the ePTFE tube has a node-fibril microstructure in which the fibrils are oriented perpendicular to the longitudinal axis of the mandrel throughout the wall thickness of the ePTFE tube.
  • a shape memory alloy stent having a nominal inner diameter of about 10 mm and being about 100 mm in length in its enlarged diametric configuration was concentrically placed over the ePTFE covered mandrel at about 22° C and positionally centrally along the longitudinal length of the ePTFE tube.
  • the inner diameter of the shape memory stent was toleranced to the outer diameter of the ePTFE tube on the mandrel and engaged about the ePTFE tube without tearing or disturbing the surface of the ePTFE tube.
  • the second ePTFE tube has a node-fibril microstructure in which the fibrils are oriented parallel to the longitudinal axis of the second ePTFE tube throughout the wall thickness of the second ePTFE tube.
  • the opposing ends of the second ePTFE tube were secured about the first ePTFE tube and the mandrel by tension wrapping with strips of TFE tape.
  • the entire assembly was then placed in a helical winding tension wrapping machine which tension wrapped the assembly with a single overlapping layer of 2 inch TFE tape in the same manner as in Example 1 to compress the ePTFE material from the first and second ePTFE tubes into intimate contact with one another through the wall openings of the stent.
  • the wrapped assembly was placed into a radiant heat furnace, which had been preheated to about a 337° C set point. The assembly remained in the furnace for about 10 minutes, and was removed. The heated assembly was allowed to cool for a period of time sufficient to permit manual handling of the assembly. After cooling, the ends of the mandrel were engaged in two rings and the TFE helical wrap was unwound from the encapsulated stent assembly and discarded.
  • the encapsulated stent assembly was then circumferentially rotated about the axis of the mandrel to break any adhesion occurring between the luminal ePTFE material and the mandrel. Excess ePTFE material from the proximal and distal ends of the encapsulated stent assembly was then laser trimmed in the manner described in Example 1 and the encapsulated stent assembly was removed from the mandrel. The encapsulated stent was then cooled to about -20 °C in a cold dry environment and allowed to equilibrate for 30 minutes.
  • the encapsulated stent was then flattened between 2 plates to bring diametrically opposed luminal wall surfaces of the encapsulated stent into contact with one another, thereby creating a flat structure without an inner lumen.
  • the encapsulated stent was then folded over itself along its longitudinal axis once, and then again for a total of one flattening operation and two folding operations.
  • the diameter of the embedded stent was reduced about 60% from it original post encapsulated diameter.
  • the device was fiilly inserted into a constraining sheath with an internal diameter of approximately 4.7 mm.
  • the folded and sheathed stent was then removed from the cold environment, and placed into a water bath maintained at a temperature of 37°C.
  • a pusher was inserted into the lumen of the constraining sheath and the encapsulated stent was ejected from the constraining sheath as described above in Example 2.
  • the stent was ejected, it unfolded from its flattened and folded state, and re-assumed the original tubular diametric configuration having a nominal inner diameter of 10 mm.
  • the third preferred embodiment of the present invention depicted in Figures 2A-2B, and consists generally of self-expanding intraluminal stent 10 made from either an elastic spring material or of a pseudoelastic shape memory material, and is at least partially encapsulated in a substantially monolithic ePTFE covering 14 while in a relatively small diametric dimension O ⁇ such that the ePTFE encapsulating covering 14 acts to impart strain upon the intraluminal stent 10 and constrain the intraluminal stent 10 from radial expansion to a relatively larger diametric dimension D 2 .
  • EXAMPLE 4 ELASTIC SPRING BALLOON DEPLOYED ENCAPSULATED STENT An encapsulated elastically self-expanding stainless steel stent was constructed by placing a 30 cm length of seamless unsintered ePTFE tube over a 3.3 mm cylindrical stainless steel mandrel. The inner diameter of the ePTFE tube was toleranced to provide a slight interference fit to the mandrel. The thickness of the ePTFE layer was measured to be about 0.35 mm by direct measurement of seamless tube wall using a snap gauge. The ePTFE tube has a node-fibril microstructure in which the fibrils are oriented parallel to the longitudinal axis ePTFE tube throughout the wall thickness of the ePTFE tube.
  • the ends of the ePTFE tube were wrapped with strips of TFE tape to retain the position of the ePTFE tube on the mandrel for the next assembly step.
  • a second seamless sintered ePTFE tube was concentrically engaged over the first ePTFE tube by first longitudinally slitting opposing ends of the ends of the second tube, then inserting the mandrel and first ePTFE tube into the lumen of the second ePTFE tube.
  • One end of the second ePTFE was wrapped with strips of Vi inch TFE tape to secure it to the first ePTFE tube and the mandrel.
  • the wall thickness of the second layer was measured as described above, and the thickness was found to be about 0.35 mm.
  • the second ePTFE tube has a node-fibril microstructure in which the fibrils are oriented parallel to the longitudinal axis of the ePTFE tube.
  • An elastic spring stainless steel stent having a nominal inner diameter of about 15 mm and a length of about 24 mm in its enlarged diametric configuration was inserted into a constraining sheath to reduce the inner diameter to about 4.0 mm. A small length of the stent is left exposed
  • the constraining sheath containing the radially constrained stent was inserted over the mandrel, and forced between the first and second ePTFE tubes such that it was positioned intermediate to the first and second ePTFE tubes.
  • the exposed end of the stent was then frictionally engaged through the second ePTFE tube wall and the constraining sheath retracted, leaving the stent positioned between the first and second ePTFE tubes.
  • the unsecured end of the second ePTFE tube was then secured to the first ePTFE tube and the mandrel with strips of 7 ⁇ inch TFE tape.
  • the assembly was then placed in a helical winding machine to tension wrap a single overlapping layer of V2 inch TFE tape, and sintered in a radiant heat furnace, cooled, the TFE tape unwrapped and the excess ePTFE laser trimmed as described in Example 1 above.
  • the resulting encapsulated stent was placed over the balloon on a 12 mm by 4 cm PTA balloon dilation catheter. The device was then placed into a temperature controlled water bath maintained at 45 ° C. The balloon was pressurized using a saline filled inflator which radially deformed the ePTFE encapsulation and permitted radial expansion of the elastically self- expanding stent. The encapsulated stent fully radially expanded to a 12 mm inner diameter at an applied pressure of 2.5 atmospheres.
  • the fourth preferred embodiment of the present invention consists generally of a self-expanding intraluminal stent 20 made from either an elastic spring material or a pseudoelastic shape memory material, which is at least partially encapsulated in a substantially monolithic ePTFE covering 14 while in a relatively larger diametric D 2 dimension such that the ePTFE encapsulating covering 14 acts as to restrain the intraluminal stent 20 from further self-expansion.
  • the encapsulated assembly is then worked, such as by crimping, calendaring, folding, or the like, to its reduced diametric dimension O 1 to achieve a profile suitable for endoluminal delivery and the assembly is then constrained by an external constraining sheath 22.
  • the constraining sheath 22 is removed to release the constraining force and the intraluminal stent 20 is permitted to elastically expand 24, carrying the ePTFE covering 14 into contact with the intraluminal tissue (Not shown).
  • a self deploying encapsulated shape memory alloy stent is constructed by placing a 40 cm length of seamless expanded PTFE tube over a 10 mm cylindrical stainless steel mandrel.
  • the inner diameter of the ePTFE tube is closely toleranced to provide a slight interference fit to the mandrel.
  • the thickness of the ePTFE layer is measured to be about 0.20 mm by taking a radial slice of the seamless tube, and evaluated by light microscopy incorporating a calibrated reticle.
  • the tubing is constructed such that the fibrils are oriented perpendicular to the longitudinal axis of the mandrel.
  • the ends of the seamless tube are wrapped with strips of TFE tape to keep the tube from sliding along the mandrel for the next assembly step.
  • a shape memory alloy stent about 10 mm inner diameter by 100 mm in length in its enlarged diametric configuration is placed over the ePTFE covered mandrel at about 22° C and centered over the ePTFE layer.
  • the inner diameter of the shape memory stent is closely toleranced to the outer diameter of the ePTFE covered mandrel.
  • a second tube of seamless expanded PTFE is placed over the stent by slitting the ends of the second tube, and inserting the mandrel, ePTFE tube, and stent assembly into the second tube.
  • the wall thickness of the second layer is measured as described above, and the thickness is found to be about 0.20 mm.
  • the fibrils are oriented perpendicular to the longitudinal axis of the mandrel.
  • the ends of the second tube are also wrapped with strips of TFE tape.
  • the assembly is then placed in a helical winding machine which wraps the assembly with a single overlapping layer of V2 inch TFE tape.
  • the overlap of the winding was about 70%.
  • the wrapping material compresses the ePTFE/Stent/ePTFE composite structure against the mandrel, causing the layers of ePTFE to come into intimate contact through the interstices of the shape memory stent.
  • the wrapped assembly is placed into a radiant heat furnace, which is preheated to a 337° C set point.
  • the assembly remains in the furnace for about 10 minutes, and removed.
  • the heated assembly is allowed to cool for a period of time sufficient to permit manual handling of the assembly.
  • the ends of the mandrel are engaged in two rings, allowing the TFE helical wrap to be unwound from the sample and discarded.
  • the ePTFE/Stent assembly is then rotated about the axis of the mandrel to break the grip of the inner ePTFE layer to the mandrel.
  • the stent sample while still on the mandrel, is placed into a fixture to allow for laser trimming of the ePTFE materials away from the embedded stent. Trimming operation is performed on
  • the encapsulated stent is then rolled between 2 plates, reducing the diameter of the stent to about 3.5 mm.
  • the diameter of the embedded stent is reduced about 40% from its original post encapsulated diameter.
  • the device While in the compressed state, the device is fully inserted into a constraining sheath with an internal bore of approximately 3.7 mm.
  • the constrained stent is placed into a water bath maintained at a temperature of 37° C.
  • a pusher was inserted into the bore of the sheath, and the stent ejected from the constraining sheath. As the stent was ejected, it unfurled from its flattened and folded state, and re-assumed the original post encapsulation tubular diametric configuration.
  • an at least partially unsintered tubular interlayer is interdisposed between the inner and outer ePTFE layers and adjacent the intraluminal stent along at least a longitudinal extent thereof.
  • the interlayer member may consist of a single tubular member which extends along at least a portion of the longitudinal axis of the intraluminal stent.
  • the interlayer member may consist of a plurality of ring-like members positioned along the longitudinal axis of the intraluminal stent and in spaced-apart relationship from one and other.
  • the interlayer member is may be preferably employed either I) where at least one of the inner and outer ePTFE tubular members of the inventive encapsulated intraluminal stent is fully sintered to formation of a monolithic joining of the inner and outer ePTFE tubular members, and/or ii) to serve as a barrier between a radiopaque marker and the intraluminal stent to insulate against galvanic corrosion resulting from contact of metal atoms in a radiopaque marker and metal in an intraluminal stent.
  • the interlayer member may be employed with any type of intraluminal stent, i.e., a shape memory alloy which behaves in either a thermoelastic or pseudoelastic manner, with a self- expanding stent in which radial expansion is a spring tension mediated event, or with a balloon expandable stent.
  • a shape memory alloy which behaves in either a thermoelastic or pseudoelastic manner, with a self- expanding stent in which radial expansion is a spring tension mediated event, or with a balloon expandable stent.
  • a thermally deployed encapsulated shape memory alloy stent was constructed by placing a 40 cm length of a first sintered seamless expanded PTFE tube over a 10 mm cylindrical
  • the inner diameter of the ePTFE tube was of a sufficient size to permit an interference fit with the mandrel.
  • the thickness of the ePTFE layer was measured to be about 0.20 mm by taking a radial slice of the seamless tube, and evaluated by light microscopy incorporating a calibrated reticle.
  • the ePTFE tube has a node-fibril microstructure in which the fibrils are oriented parallel to the longitudinal axis of the mandrel throughout the wall thickness of the ePTFE tube. The ends of the ePTFE tube were wrapped with TFE tape to keep the tube from sliding along the mandrel for the next assembly step.
  • a shape memory alloy stent having a nominal inner diameter of about 10 mm and being about 100 mm in length in its enlarged diametric configuration was concentrically placed over the ePTFE covered mandrel at about 22° C and positionally centrally along the longitudinal length of the ePTFE tube.
  • the inner diameter of the shape memory stent was toleranced to the outer diameter of the ePTFE tube on the mandrel and engaged about the ePTFE tube without tearing or disturbing the surface of the ePTFE tube.
  • a pair of unsintered ePTFE rings prepared by wrapping unsintered ePTFE films concentrically about each of the opposing ends of the shape memory alloy stent and the first sintered ePTFE tube, such that the node and fibril microstructure of the unsintered ePTFE rings had a fibril orientation perpendicular to the fiber orientation of the first ePTFE tube and the longitudinal axis of the stent.
  • the second ePTFE tube has a node-fibril microstructure in which the fibrils are oriented parallel to the longitudinal axis of the second ePTFE tube throughout the wall thickness of the second ePTFE tube.
  • the opposing ends of the second ePTFE tube were secured about the first ePTFE tube and the mandrel by tension wrapping with strips of TFE tape.
  • Example 2 The entire assembly was then placed in a helical winding tension wrapping machine which tension wrapped the assembly with a single overlapping layer of Vi inch TFE tape in the same manner as in Example 1 to compress the ePTFE material from the first and second ePTFE tubes into intimate contact with one another through the wall openings of the stent.
  • the wrapped assembly was placed into a radiant heat furnace, which had been preheated to about a 337° C set point.
  • the assembly remained in the furnace for about 10 minutes, and was
  • the heated assembly was allowed to cool for a period of time sufficient to permit manual handling of the assembly. After cooling, the ends of the mandrel were engaged in two rings and the TFE helical wrap was unwound from the encapsulated stent assembly and discarded. The encapsulated stent assembly was then circumferentially rotated about the axis of the mandrel to break any adhesion occurring between the luminal ePTFE material and the mandrel. Excess ePTFE material from the proximal and distal ends of the encapsulated stent assembly was then laser trimmed in the manner described in Example 1 and the encapsulated stent assembly was removed from the mandrel.
  • the encapsulated stent was then cooled to about -20 °C in a cold dry environment and allowed to equilibrate for 30 minutes.
  • the encapsulated stent was then flattened between 2 plates to bring diametrically opposed luminal wall surfaces of the encapsulated stent into contact with one another, thereby creating a flat structure without an inner lumen.
  • the encapsulated stent was then folded over itself along its longitudinal axis once, and then again for a total of one flattening operation and two folding operations.
  • the diameter of the embedded stent was reduced about 60% from it original post encapsulated diameter. While still in the cold, dry environment, the device was fully inserted into a constraining sheath with an internal diameter of approximately 4.7 mm.
  • the folded and sheathed stent was then removed from the cold environment, and placed into a water bath maintained at a temperature of 37° C.
  • a pusher was inserted into the lumen of the constraining sheath and the encapsulated stent was ejected from the constraining sheath as described above in Example 2.
  • the stent was ejected, it unfolded from its flattened and folded state, and re-assumed the original tubular diametric configuration having a nominal inner diameter of 10 mm.
  • interlayer member employed in the foregoing Example 6 was a sheet of unsintered ePTFE material, it will also be appreciated that tubular or ring-like unsintered ePTFE members may be employed.
  • the interlayer member is a tubular or ring-like unsintered ePTFE member
  • the interlayer member will preferably have a node and fibril microstructure in which the fibril orientation of the interlayer member is parallel to the longitudinal axis of the interlayer member and parallel with the fibril orientation of the inner and outer ePTFE tubular members which the interlayer member is interdisposed between.
  • thermoelastic transformation of a shape memory intraluminal stent care must be taken to 1) avoid imparting a secondary shape memory to the shape memory alloy during sintering of the ePTFE encapsulating covering, 2) avoid inducing stress-induced martensite formation during thermomechanical forming for either encapsulation or mounting onto a delivery catheter, and 3) avoid inducing non-recoverable strains by exceeding the strain limit of the shape memory alloy material used.
  • the elastic behavior of a stent made of either a pseudoelastic shape memory alloy or a spring tension material care must be taken to avoid plastically deforming the stent which would deleteriously effect the elastic deformation property of the intraluminal stent during intraluminal delivery.
  • the stress-induced martensite phase will be induced in the shape memory alloy during deformation of the stent to a diametric dimension suitable for endoluminal delivery and maintained so that when the encapsulated stent, in the stress-induced martensite state is delivered and either the ePTFE constraint or the constraining sheath is relieved, the strain is released and the stent, in the stress-induced martensite phase is permitted to transform to austenite and the stent to elastically deform to its pre-programed diametric dimension.
  • FIGS 9A-9B are process flow diagrams setting forth the fundamental method steps of the methods to make each of the above-described preferred embodiments.
  • a shape memory intraluminal stent is to be encapsulated in an ePTFE covering
  • thermoelastic transformation of the shape memory stent is desired, either in a balloon assisted expandable encapsulated stent embodiment or in a self-expanding encapsulated stent embodiment
  • the thermoelastic deformation of the shape memory stent from its enlarged diametric dimension D 2 to its reduced diametric dimension Dj may be accomplished in accordance with the method 40 set forth in Figure 9 A.
  • Thermoelastic deformation method 40 entails first providing an shape memory alloy intraluminal stent having a predetermined shape memory configuration 42. The intraluminal stent is then exposed to a temperature below the martensite transformation temperature M, of the shape memory alloy 44
  • the stent While still below the M s temperature, the stent is mechanically deformed to reduce its diameter from the enlarged diametric dimension D 2 to a reduced diametric dimension D x suitable for endoluminal delivery.
  • the stent at its reduced diametric dimension is now at a dimensional state suitable for encapsulation at its reduced diametric dimension D t .
  • the encapsulation method 60 is more fully set forth in Figure 9B, and is applicable for either a shape memory alloy intraluminal stent which is to be encapsulated either at its reduced diametric dimension D t or at its enlarged diametric dimension D 2 as well as for a self-expanding stent which radially expands due to inherent spring tension in the stent.
  • a luminal ePTFE tube 62 is concentrically engaged upon a mandrel 64 and secured to the mandrel. Either a shape memory stent or a self-expanding stent is selected at step 66.
  • a shape memory stent is selected 70, the shape memory stent 52 is engaged over the luminal ePTFE tube at step 54 while maintaining the stent at a temperature below A s to prevent the stent from radially expanding.
  • a self-expanding stent is selected 68, an abluminal ePTFE tube is concentrically engaged over the luminal ePTFE tube and the self-expanding stent 80 interdisposed between the luminal and abluminal ePTFE tubes and secured there between 78.
  • a shape memory alloy intraluminal stent is employed 74, the abluminal ePTFE tube is concentrically engaged over the stent.
  • the entire assembly is then wrapped with TFE tape 82 to exert a circumferential pressure about the entire circumference of both the luminal and abluminal ePTFE tubes and the stent, causing the ePTFE tubes to be motivated into intimate contact with one and other through the interstices of the stent.
  • the entire wrapped assembly is then sintered 84 and excess ePTFE overlaying ends of the stent may be trimmed 86.
  • the encapsulated stent is then prepared for mounting onto a delivery catheter 88, either by mounting the encapsulated stent in its reduced diametric dimension D x onto a balloon catheter for balloon-assisted delivery, or by thermomechanical deformation from the enlarged diametric dimension D 2 to the reduced diametric dimension O l following the method steps of thermomechanical deformation 40 or formation of stress-induced martensite for pseudoelastic recovery by crimping, folding or otherwise reducing the encapsulated stent to its reduced diametric dimension D 1; mounting onto a delivery catheter and applying an external constraining sheath concentrically over the encapsulated stent.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Transplantation (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Cardiology (AREA)
  • Surgery (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Prostheses (AREA)
  • Media Introduction/Drainage Providing Device (AREA)
  • Materials For Medical Uses (AREA)

Abstract

Stents endoluminaux constitués d'un alliage à mémoire de forme, à auto-expansion élastique, qui sont au moins partiellement encapsulés dans une enveloppe en polytétrafluoroéthylène expansé (PTFEe) sensiblement monolithique. Un stent endoluminal, ayant un diamètre réduit lors de son introduction dans la lumière vasculaire et un diamètre final in vivo plus important, est encapsulé dans une enveloppe en PTFEe, qui recouvre circonférentiellement aussi bien sa paroi luminale que sa paroi abluminale sur au moins une partie de sa longueur. Ce stent endoluminal à mémoire de forme est constitué d'un alliage à mémoire de forme possédant soit une mémoire de forme, soit des propriétés pseudo-élastiques, ou bien d'un matériau élastique possédant une tension de ressort propre.
PCT/US1998/008994 1998-02-02 1998-05-04 Stent-greffon intraluminal encapsule et procede de fabrication associe WO1999038455A1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP98918939A EP1054646A1 (fr) 1998-02-02 1998-05-04 Stent-greffon intraluminal encapsule et procede de fabrication associe
JP2000529191A JP4057238B2 (ja) 1998-02-02 1998-05-04 封入された管腔内ステント−移植片の製造法
AU71759/98A AU733860B2 (en) 1998-02-02 1998-05-04 Encapsulated intraluminal stent-graft and methods of making same
CA002318829A CA2318829C (fr) 1998-02-02 1998-05-04 Stent-greffon intraluminal encapsule et procede de fabrication associe

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
USPCT/US98/02361 1998-02-02
PCT/US1998/002361 WO1998033453A2 (fr) 1997-02-05 1998-02-02 Implants tubulaires en polytetrafluorethylene radialement extensibles et leur procede de fabrication

Publications (1)

Publication Number Publication Date
WO1999038455A1 true WO1999038455A1 (fr) 1999-08-05

Family

ID=22266351

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/008994 WO1999038455A1 (fr) 1998-02-02 1998-05-04 Stent-greffon intraluminal encapsule et procede de fabrication associe

Country Status (5)

Country Link
EP (1) EP1054646A1 (fr)
JP (1) JP4057238B2 (fr)
AU (1) AU733860B2 (fr)
CA (1) CA2318829C (fr)
WO (1) WO1999038455A1 (fr)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6379382B1 (en) 2000-03-13 2002-04-30 Jun Yang Stent having cover with drug delivery capability
US6613082B2 (en) 2000-03-13 2003-09-02 Jun Yang Stent having cover with drug delivery capability
WO2007127083A1 (fr) * 2006-04-21 2007-11-08 Gore Enterprise Holdings, Inc. Endoprothese expansible recouverte ayant un large eventail de diametres deployes sans plis
FR2904560A1 (fr) * 2006-08-07 2008-02-08 Patrice Bergeron Endoprothese et systeme comprenant une telle endoprothese
US8267989B2 (en) 2004-01-30 2012-09-18 Trivascular, Inc. Inflatable porous implants and methods for drug delivery
US8652193B2 (en) 2005-05-09 2014-02-18 Angiomed Gmbh & Co. Medizintechnik Kg Implant delivery device
US8721704B2 (en) 2006-04-21 2014-05-13 W. L. Gore & Associates, Inc. Expandable stent with wrinkle-free elastomeric cover
US8992595B2 (en) 2012-04-04 2015-03-31 Trivascular, Inc. Durable stent graft with tapered struts and stable delivery methods and devices
US9498363B2 (en) 2012-04-06 2016-11-22 Trivascular, Inc. Delivery catheter for endovascular device
US9867727B2 (en) 1998-02-09 2018-01-16 Trivascular, Inc. Endovascular graft
US10159557B2 (en) 2007-10-04 2018-12-25 Trivascular, Inc. Modular vascular graft for low profile percutaneous delivery
US10245137B2 (en) 2013-07-22 2019-04-02 Atrium Medical Corporation Graft with expandable region and methods of making and using the same
WO2022182348A1 (fr) * 2021-02-25 2022-09-01 W. L. Gore & Associates, Inc. Dispositifs de confinement implantables géométriquement déformables destinés à la rétention de fractions biologiques

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7270675B2 (en) 2002-05-10 2007-09-18 Cordis Corporation Method of forming a tubular membrane on a structural frame
US7485141B2 (en) 2002-05-10 2009-02-03 Cordis Corporation Method of placing a tubular membrane on a structural frame
US8088158B2 (en) 2002-12-20 2012-01-03 Boston Scientific Scimed, Inc. Radiopaque ePTFE medical devices
CA2577108A1 (fr) 2004-08-31 2006-03-09 C.R. Bard, Inc. Greffe en polytetrafluorethylene (ptfe) auto-etanche a resistance au tortillement
EP1945138A4 (fr) 2005-11-09 2010-02-10 Bard Inc C R Greffons et stents-greffons presentant un marqueur radio-opaque
JP5657943B2 (ja) * 2010-08-02 2015-01-21 株式会社カネカ ステントデリバリーカテーテルの製造方法
US9775933B2 (en) 2012-03-02 2017-10-03 W. L. Gore & Associates, Inc. Biocompatible surfaces and devices incorporating such surfaces
JPWO2022030085A1 (fr) * 2020-08-03 2022-02-10

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995005132A1 (fr) * 1993-08-18 1995-02-23 W.L. Gore & Associates, Inc. Greffon endoluminal servant d'extenseur
EP0686379A2 (fr) * 1994-06-08 1995-12-13 Cardiovascular Concepts, Inc. Appareil pour la pose d'une greffe endoluminale
WO1996000103A1 (fr) * 1994-06-27 1996-01-04 Endomed, Inc. Polytetrafluoroethylene expanse radialement, et extenseurs endovasculaires expansibles formes avec cette matiere
WO1996028115A1 (fr) * 1995-03-10 1996-09-19 Impra, Inc. Extenseur encapsule endoluminal, son procede de fabrication, et son procede d'implantation endoluminale
WO1997007751A1 (fr) * 1995-08-24 1997-03-06 Impra, Inc. Extenseur endoluminal recouvert et procede d'assemblage
WO1997021403A1 (fr) * 1995-12-14 1997-06-19 Prograft Medical, Inc. Stent a greffer resistant aux plis

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995005132A1 (fr) * 1993-08-18 1995-02-23 W.L. Gore & Associates, Inc. Greffon endoluminal servant d'extenseur
EP0686379A2 (fr) * 1994-06-08 1995-12-13 Cardiovascular Concepts, Inc. Appareil pour la pose d'une greffe endoluminale
WO1996000103A1 (fr) * 1994-06-27 1996-01-04 Endomed, Inc. Polytetrafluoroethylene expanse radialement, et extenseurs endovasculaires expansibles formes avec cette matiere
WO1996028115A1 (fr) * 1995-03-10 1996-09-19 Impra, Inc. Extenseur encapsule endoluminal, son procede de fabrication, et son procede d'implantation endoluminale
WO1997007751A1 (fr) * 1995-08-24 1997-03-06 Impra, Inc. Extenseur endoluminal recouvert et procede d'assemblage
WO1997021403A1 (fr) * 1995-12-14 1997-06-19 Prograft Medical, Inc. Stent a greffer resistant aux plis

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9867727B2 (en) 1998-02-09 2018-01-16 Trivascular, Inc. Endovascular graft
US10548750B2 (en) 1998-02-09 2020-02-04 Trivascular, Inc. Endovascular graft
US6613082B2 (en) 2000-03-13 2003-09-02 Jun Yang Stent having cover with drug delivery capability
US6613084B2 (en) 2000-03-13 2003-09-02 Jun Yang Stent having cover with drug delivery capability
US6379382B1 (en) 2000-03-13 2002-04-30 Jun Yang Stent having cover with drug delivery capability
US8267989B2 (en) 2004-01-30 2012-09-18 Trivascular, Inc. Inflatable porous implants and methods for drug delivery
US8652193B2 (en) 2005-05-09 2014-02-18 Angiomed Gmbh & Co. Medizintechnik Kg Implant delivery device
WO2007127083A1 (fr) * 2006-04-21 2007-11-08 Gore Enterprise Holdings, Inc. Endoprothese expansible recouverte ayant un large eventail de diametres deployes sans plis
US8425584B2 (en) 2006-04-21 2013-04-23 W. L. Gore & Associates, Inc. Expandable covered stent with wide range of wrinkle-free deployed diameters
US8721704B2 (en) 2006-04-21 2014-05-13 W. L. Gore & Associates, Inc. Expandable stent with wrinkle-free elastomeric cover
US8721819B2 (en) 2006-04-21 2014-05-13 W. L. Gore & Asociates, Inc. Methods for an expandable covered stent with wide range of wrinkle-free deployed diameters
EP1891994A1 (fr) * 2006-08-07 2008-02-27 Patrice Bergeron Endoprothèse et système comprenant une telle endoprothèse
FR2904560A1 (fr) * 2006-08-07 2008-02-08 Patrice Bergeron Endoprothese et systeme comprenant une telle endoprothese
US10159557B2 (en) 2007-10-04 2018-12-25 Trivascular, Inc. Modular vascular graft for low profile percutaneous delivery
US10682222B2 (en) 2007-10-04 2020-06-16 Trivascular, Inc. Modular vascular graft for low profile percutaneous delivery
US12016766B2 (en) 2007-10-04 2024-06-25 Trivascular, Inc. Modular vascular graft for low profile percutaneous delivery
US8992595B2 (en) 2012-04-04 2015-03-31 Trivascular, Inc. Durable stent graft with tapered struts and stable delivery methods and devices
US9498363B2 (en) 2012-04-06 2016-11-22 Trivascular, Inc. Delivery catheter for endovascular device
US10245137B2 (en) 2013-07-22 2019-04-02 Atrium Medical Corporation Graft with expandable region and methods of making and using the same
US11406487B2 (en) 2013-07-22 2022-08-09 Atrium Medical Corporation Graft with expandable region and methods of making and using the same
WO2022182348A1 (fr) * 2021-02-25 2022-09-01 W. L. Gore & Associates, Inc. Dispositifs de confinement implantables géométriquement déformables destinés à la rétention de fractions biologiques

Also Published As

Publication number Publication date
EP1054646A1 (fr) 2000-11-29
AU7175998A (en) 1999-08-16
JP4057238B2 (ja) 2008-03-05
CA2318829C (fr) 2007-11-13
JP2002501779A (ja) 2002-01-22
CA2318829A1 (fr) 1999-08-05
AU733860B2 (en) 2001-05-31

Similar Documents

Publication Publication Date Title
US6451047B2 (en) Encapsulated intraluminal stent-graft and methods of making same
CA2318829C (fr) Stent-greffon intraluminal encapsule et procede de fabrication associe
EP1041941B2 (fr) Implant a support
US6402779B1 (en) Balloon-assisted intraluminal stent graft
JP4728349B2 (ja) ｅＰＴＦＥの製造方法及び血管グラフトのようなｅＰＴＦＥを備える構造

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2318829

Country of ref document: CA

Ref country code: CA

Ref document number: 2318829

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1998918939

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 71759/98

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 1998918939

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 71759/98

Country of ref document: AU

WWW Wipo information: withdrawn in national office

Ref document number: 1998918939

Country of ref document: EP